Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects

Diagnostic Microbiology and Infectious Disease

Volumn 50, Issue 2, 2004, Pages 95-102

  Bhavnani, Sujata M ^a,b   Owen, Joel S ^a,c   Loutit, Jeffery S ^d   Porter, Steven B ^d   Ambrose, Paul G ^a,b  

^a Albany Medical College   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c AUBURN UNIVERSITY   (United States)

^d InterMune Inc   (United States)

Author keywords

First time in man; Glycopeptide; Oritavancin; Pharmacokinetics; Safety

Indexed keywords

ORITAVANCIN;

ADULT; ANTIMICROBIAL ACTIVITY; ANXIETY DISORDER; ARTICLE; BLOOD ANALYSIS; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; DYSPNEA; EAR DISEASE; ECZEMA; EPISTAXIS; EYE DISEASE; FECES ANALYSIS; FEMALE; FLATULENCE; HEADACHE; HERPES SIMPLEX; HUMAN; INSOMNIA; LABORATORY TEST; MALAISE; MALE; NAIL DISEASE; NORMAL HUMAN; OLIGURIA; OTALGIA; PAIN; PARANOIA; PHARYNGITIS; PRIORITY JOURNAL; PRURITUS; RASH; RECTUM DISEASE; RHINITIS; SKIN DISEASE; STOMATITIS; UNPLEASANT DREAM; URINALYSIS; URINE RETENTION; VERTIGO;

ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLYCOPEPTIDES; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PROSPECTIVE STUDIES; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY;

EID: 5044238495     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2004.06.007     Document Type: Article

References (25)

1. rd ICAAC Abstracts, American Society for Microbiology, Chicago, IL
2. rd ICAAC Abstracts, American Society for Microbiology, Chicago, IL
3. Boylan C.J., Campanale K., Iversen P.W., Phillips D.L., Zeckel M.L., Parr T.R. Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother. 47:2003;1700-1706
4. Brumfitt W. Franklin I, Grady D, Hamilton-Miller JM, Iliffe A (1984). Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers. Antimicrob Agents Chemother 26, 757-761
5. nd ICAAC Abstracts, American Society for Microbiology, San Diego, CA
6. Donskey C.J., Chowdhry T.K., Hecker M.T., Hoyen C.K., Hanrahan J.A., Hujer A.M., Hutton-Thomas R.A., Whalen C.C., Bonomo R.A., Rice L.B. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med. 343:2000;1925-1932
7. nd ICAAC American Society for Microbiology, San Diego, CA
8. Edlund C, Sjostedt S, Nord CE (1997). Comparative effects of levofloxacin and ofloxacin on the normal oral and intestinal microflora. Scand J Infect Dis 29,383-386
9. Gerber J., Smirnow A., Wellmer A., Raghab J., Prange J., Schutz E., Wettich K., Kalich S., Nau R. Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin. Antimicrob Agents Chemother. 45:2001;2169-2172
10. rd ICAAC Abstracts, American Society for Microbiology, Chicago, IL
11. th ed. :1986;398 W. B. Saunders Company, Philadelphia, PA
12. Lefort A.A., Saleh-Jghir A., Garry L., Carbon C., Fantin B. Activity of LY333328 combined with gentamicin in vitro and in vivo in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis. Antimicrob Agents Chemother. 44:2000;3017-3021
13. Nord C.E. Effect of the new quinolones on the human gastrointestinal microflora. Rev Infect Dis. 10 (Suppl 1):1988;S193-S196
14. Polk R.E. Anaphylactoid reactions to glycopeptide antibiotics. J Antimicrob Chemother. 24:1991;17-29
15. st ICAAC Abstracts, American Society for Microbiology, Chicago, IL
16. Rowland R. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet. 18:1990;184-209
17. th ICAAC Abstracts, American Society for Microbiology, San Diego, CA
18. rd ICAAC Abstracts, American Society for Microbiology, Chicago, IL
19. rd ICAAC Abstracts, American Society for Microbiology, Chicago, IL
20. Steiert M., Schmitz F.J. Dalbavancin (Biosearch Italia/Versicor). Curr Opin Investig Drugs. 3:2002;229-233
21. Vancocin® HCl. Product Information. Eli Lilly and Company. June 17, 1997
22. st ICAAC Abstracts, American Society for Microbiology, Chicago, IL
23. Wilson A.P. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet. 39:2000;167-183
24. Zeckel M.L., Preston D.A., Allen B.S. In vitro activities of LY333328 and comparative agents against nosocomial Gram-positive pathogens collected in a 1997 global surveillance study. Antimicrob Agents Chemother. 44:2000;1370-1374
25. Zhanel G.G., Kirkpatrick I.D.C., Hoban D.J., Kabani A.M., Karlowshy J.A. Influence of human serum on pharmacodynamic properties of an investigational glycopeptide LY333328, and comparator agents against Staphylococcus aureus. Antimicrob Agents Chemother. 42:1998;2427-2430